The FDA has approved the next-generation of the multitarget stool DNA test Cologuard (Exact Sciences) in adults aged 45 years and older who are at average risk for colorectal cancer.
The update, called Cologuard Plus, touts increased sensitivity and specificity rates due to “novel biomarkers and improved laboratory processes,” according to the company.
“Exact Sciences saw the need to try to improve upon how the test performed, especially its specificity,” said